In Brief: Benzodiazepines
Benzodiazepines: Public hearing on abuse potential and controlled substance scheduling criteria for benzodiazepines will be held by FDA Sept. 11-12. The meeting will address whether different benzodiazepines may be distinguishable according to their abuse potential. Carter-Wallace has petitioned for the descheduling of its benzodiazepine Doral (quazepam). The hearing will be held at the Renaissance Hotel in Washington, D.C. beginning at 9 a.m. both days...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth